ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q2Scopus Q2SCImago #5,913Hybrid

European Journal of Clinical Pharmacology

Acronym:ejcl
•
Abbreviation (ISO):EUR J CLIN PHARMACOL
•
Identifier (ISSN):0031-6970(Print)/1432-1041(Online)
•
Publisher:Springer Berlin Heidelberg
Clarivate IF (2026)
3.5↑ +0.8
Journal Impact Factor
IF Trend↓
WoS Quartile
Q2
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for European Journal of Clinical Pharmacology

WoS Q2
12452.6820182.7720192.6420202.9520213.0620222.920232.420242.720253.52026
Annual Impact Factor Metric
Current (2026):3.5
Scopus SJR & RankScopus Q2
0.886
#5,913

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
128

128 papers with at least that number of citations each

WoS: SCIE / JCRQ2
Self-Citation Rate4.2%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
151articles/year
29.41% Gold OA•74.07% Original Research

Aims & Scope

The European Journal of Clinical Pharmacology publishes original papers on all aspects of clinical pharmacology and drug therapy in humans. Manuscripts are welcomed on the following topics: therapeutic trials, pharmacokinetics/pharmacodynamics, pharmacogenetics, drug metabolism, adverse drug reactions, drug interactions, all aspects of drug development, development relating to teaching in clinical pharmacology, pharmacoepidemiology, and matters relating to the rational prescribing and safe use of drugs. Methodological contributions relevant to these topics are also welcomed. Data from animal experiments are accepted only in the context of original data in man reported in the same paper. EJCP will only consider manuscripts describing the frequency of allelic variants in different populations if this information is linked to functional data or new interesting variants. Highly relevant differences in frequency with a major impact in drug therapy for the respective population may be submitted as a letter to the editor. Straightforward phase I pharmacokinetic or pharmacodynamic studies as parts of new drug development will only be considered for publication if the paper involves -a compound that is interesting and new in some basic or fundamental way, or -methods that are original in some basic sense, or -a highly unexpected outcome, or -conclusions that are scientifically novel in some basic or fundamental sense.

Topics Covered (Recognized by AI)
Medicine99.6%Biology96.2%Internal medicine90%Pharmacology77.8%Chemistry68.9%Endocrinology61.6%Biochemistry55.5%Psychology45.6%Genetics43.3%Bioinformatics40.1%Pathology39.7%Psychiatry39.5%Pharmacokinetics34.5%Anesthesia33.8%Organic chemistry30.9%Surgery28.7%Physics24.7%
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank134/356
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank161/356
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF3.5
Articles / Year239
Total Citations103
2025
IF2.7
Articles / Year148
Total Citations375
2024
IF2.4
Articles / Year181
Total Citations1,280
2023
IF2.9
Articles / Year165
Total Citations1,630
2022
IF3.064
Articles / Year192
Total Citations1,968

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #5,913Scopus Q2SCImago Profile
Scopus Coverage:1968-2026
Scopus Broad Areas:MedicinePharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q2
0.886

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
3.48

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,183 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,680
3-Year Documents549
Citable Documents494

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate44.3%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Medicine (miscellaneous)Q2
PharmacologyQ2
Pharmacology (medical)Q2
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 4.2%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区PHARMACOLOGY & PHARMACY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

European Journal of Clinical Pharmacology (acronym: ejcl, abbr: EUR J CLIN PHARMACOL, ISSN: 0031-6970) is a peer-reviewed international scholarly journal in the field of Medicine, published by Springer Berlin Heidelberg in Germany since 1968. The periodical holds a Journal Impact Factor (JIF) of 3.50, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.886 (Q2), an H-index of 128.

The journal enforces rigorous peer evaluation with a publication frequency of Monthly, an annual output of approximately 151 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,183 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Springer Berlin Heidelberg
Publication Language
English
Frequency
Monthly
Founding Year
1968
Indexing & Databases
SCIEScopusPubMed
Editorial Address
SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: bba75cf9-e17b-4515-b55c-a28c795cfb4d
Database Updated: 2026-09-30